share_log

賽生藥業:根據《收購守則》規則22作出的交易披露

SCICLONE PHARMA: Disclosure of Dealings under Rule 22 of the Takeovers Code

Hong Kong Stock Exchange ·  Apr 19 04:45
Summary by Moomoo AI
赛生药业於2024年4月19日宣布,公司執行人員趙宏根據香港《公司收購及合併守則》規則22,於2024年4月18日透過協議安排進行了一項股票期權交易。該交易涉及2,000,000份股票期權,行使期限自當日起至2030年4月18日,行使價為每股7.8920港元。此次交易後,趙宏持有的賽生药业股份總數達到19,098,742股。該交易是根據賽生药业的購股權激勵計劃進行,並且是為本身帳戶進行的。
赛生药业於2024年4月19日宣布,公司執行人員趙宏根據香港《公司收購及合併守則》規則22,於2024年4月18日透過協議安排進行了一項股票期權交易。該交易涉及2,000,000份股票期權,行使期限自當日起至2030年4月18日,行使價為每股7.8920港元。此次交易後,趙宏持有的賽生药业股份總數達到19,098,742股。該交易是根據賽生药业的購股權激勵計劃進行,並且是為本身帳戶進行的。
SAI PHARMACEUTICALS ANNOUNCED ON 19 APRIL 2024 THAT ITS EXECUTIVE OFFICER, ZHAO HUNG, PURSUANT TO RULE 22 OF THE HONG KONG CODE OF COMPANIES ACQUISITIONS AND MERGERS, CONDUCTED A SHARE OPTION TRANSACTION BY AGREEMENT ON 18 APRIL 2024. The transaction involves 2,000,000 share options with a period of exercise from 18 April 2030 at an exercise price of HK$7.8920 per share. After this transaction, Zhao Hong's total shares of Caisang Pharmaceuticals reached 19,098,742 shares. The transaction was conducted under the Sai Sai Pharmaceutical Company's Share Option Incentive Scheme and was conducted for its own account.
SAI PHARMACEUTICALS ANNOUNCED ON 19 APRIL 2024 THAT ITS EXECUTIVE OFFICER, ZHAO HUNG, PURSUANT TO RULE 22 OF THE HONG KONG CODE OF COMPANIES ACQUISITIONS AND MERGERS, CONDUCTED A SHARE OPTION TRANSACTION BY AGREEMENT ON 18 APRIL 2024. The transaction involves 2,000,000 share options with a period of exercise from 18 April 2030 at an exercise price of HK$7.8920 per share. After this transaction, Zhao Hong's total shares of Caisang Pharmaceuticals reached 19,098,742 shares. The transaction was conducted under the Sai Sai Pharmaceutical Company's Share Option Incentive Scheme and was conducted for its own account.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more